,trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['congrat', 'bcsm', 'breast', 'destiny-breast04']
destiny-breast04 did not disappoint! t-dxd benefit over chemotherapy in her2-low previously treated advanced bc regardless of hr status hazard ratio=0.5. congrats dr modi and investigators #asco22 #plenary #bcsm 
CME experts Sara Fagerlie, PhD, CHCP and Mindy Tanzola, PhD founded Front Row CME to help clinicians and educators manage the oncology information deluge.